Healthcare CRO Market Size Worth $51.3 Billion by 2024: Grand View Research, Inc.

SAN FRANCISCO, May 15, 2018 /PRNewswire/ --

The global healthcare contract research organization (CRO) market [https://www.grandviewresearch.com/industry-analysis/healthcare-contract-research-outsourcing-market?utm_source=pressrelease&utm_medium=referral&utm_campaign=PRN_May15_Healthcare_CRO_RD1&utm_content=Content ] is expected to reach USD 51.3 billion by 2024, according to a new study by Grand View Research Inc. Increasing drug development cost is expected to drive market demand over the forecast period. With the increasing number of patents expiring, increasing number of partnerships to identify biologics and new compounds and growing R&D costs, drug maker and sponsor companies are under pressure to replace the revenue loss specifically due to generics, which has further made drug development more expensive and complex.

(Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg )

Moreover, owing to the increasing incidence rates of chronic diseases such as cancer, Alzheimer's and other infectious diseases in children, government funding has increased, which have led to increasing R&D activities. For instance, in January 2015, the U.S. announced an investment of USD 215 million for precision medicine initiative. The investment was broken up for NIH (USD 130 million), NCI (USD 70 million), and FDA (USD 10 million).

In addition, growing pressure on industry players to follow stringent timelines has increased the demand for outsourcing of research activities. Even government organizations are outsourcing their clinical trial activities to CROs so that they can carry out the clinical trials with the required infrastructure, expertise, and minimize cost and timelines. In 2015, the Canadian Federal Budget made an investment of USD 1.33 billion for the Canada Foundation for Innovation (CFI).

Browse full research report with TOC on "Healthcare Contract Research Organization (CRO) Market Size, Share & Trends Analysis Report By Type (Drug Discovery, Pre-Clinical, Clinical), By Service, By Region, And Segment Forecasts, 2018 - 2024" at: https://www.grandviewresearch.com/industry-analysis/healthcare-contract-research-outsourci ng-market [https://www.grandviewresearch.com/industry-analysis/healthcare-contract-research-outsourcing-market?utm_source=pressrelease&utm_medium=referral&utm_campaign=PRN_May15_Healthcare_CRO_RD2&utm_content=Content ]

Further Key Findings From the Report Suggest: 

        
        - Clinical trial services dominated the market in 2016 owing to the fact that it
          comprises four elaborate phases including human subjects. The increasing complexities
          in R&D trends have raised the need for expertise, thereby shortening the time required
          to commercialize the molecule.
        - In January 2016, Charles River Laboratories International, Inc. entered into a
          definitive agreement to acquire WIL Research for approximately USD 585 million. The
          acquisition is expected to strengthen Charles' ability to partner with global clients.
        - The high R&D spending in oncology has also fueled the need for healthcare contract
          research outsourcing. Realizing this demand, France-based laboratory, XenTech
          increased its capacity of its animal care to 50% along with increasing collaborative
          research projects.
        - North America was the largest regional market with revenue share estimated at over 40%
          owing to the presence of global industries, which invest maximum of their revenue in
          research activities. In addition, many academic institutes receive grants to undertake
          these activities. For instance, in July 2015, the University of Toronto received USD
          1.5 billion under the Medicine by Design initiative.
        - Europe was the second largest market in 2016. This is attributed to the tax benefits
          offered to the large and small-scale companies to promote more contract research
          outsourcing activities. The large companies can claim 30% deducible from the income of
          their R&D expenditure. In case of small and medium sized enterprises, it is 225% for
          the R&D expenditure.
        - Asia Pacific is the fastest growing industry due to the reduced cost it offers in
          comparison to the U.S and other developed economies. Increasing incidence rate of
          chronic and lifestyle diseases such as heart disease and diabetes coupled with ease in
          patient recruitment and available expertise for the clinical trials are few drivers
          propelling growth of the Asian healthcare CRO market.
        - China and India are projected to witness tremendous growth in the contract research
          outsourcing market owing to their treatment naive patient pool coupled with disease
          prevalence rate. Furthermore, genetically diverse population, highly qualified
          English-speaking investigators, well equipped hospitals are other opportunities
          offered by India for global clinical trials.
        - In July 2014, Catalent Pharma Solutions opened its oral formulation development lab in
          Japan. The laboratory, which opened in September, also expanded its CMO manufacturing
          capacity in the same lab.
        - CROs are in a process of continuously improving their portfolio by integrating
          services with technology. This enables them to save more on time and deliver efficient
          and desired results to the clients. In October 2015, PPD joined hand with Oracle to
          use its cloud technology named Oracle Siebel CTMS.
        - In addition to offering improved services, CROs are in the process of collaborating to
          promote their services at a global level. For instance, in May 2014, ClinDatrix, Inc.
          collaborated with six other CRO's to offer services to multinational clinical trials.
          The collaboration will strengthen its presence globally apart from the U.S. and
          Canada.
        - Major contributors are Quintiles, Covance, Pharmaceutical Product Development, LLC
          (PPD), Parexel, Charles River Laboratories (CRL), ICON plc, inVentiv Health, Medidata
          Solutions, and Theorem Clinical Research. According to the US database of trials,
          Parexel, Quintiles and PPD are involved in large number of collaboration with the
          sponsors pertaining to clinical trials.
        - In April 2015, Pfizer selected PPD as its third most preferred CRO. PPD has assisted
          Pfizer in extending its global reach that is expected to advance Pfizer's growing
          portfolio. Furthermore, in June 2015 Aeterna Zentaris selected Ergomed for phase III
          study to identify the efficacy of Macrelin, a novel orally active ghrelin agonist to
          evaluate AGHD.

Browse related reports by Grand View Research: 

        
        - Telemedicine Technology Market
          [https://www.grandviewresearch.com/industry-analysis/telemedicine-technology-market?utm_source=pressrelease&utm_medium=referral&utm_campaign=PRN_May15_Healthcare_CRO_RD1&utm_content=Content ]
           - Global Telemedicine Technology market is expected to experience 
          rapid growth over the forecast period owing to increasing health concerns across the
          world.

        
        - Chemoinformatics Market
          [https://www.grandviewresearch.com/industry-analysis/chemoinformatics-market?utm_source=pressrelease&utm_medium=referral&utm_campaign=PRN_May15_Healthcare_CRO_RL2&utm_content=Content ]
          - The global chemoinformatics market was valued at USD 4.43 Billion in 
          2015.

        
        - Computerized Physician Order Entry Market
          [https://www.grandviewresearch.com/industry-analysis/computerized-physician-order-entry-cpoe-market?utm_source=pressrelease&utm_medium=referral&utm_campaign=PRN_May15_Healthcare_CRO_RL3&utm_content=Content ]
          - The global computerized physician/provider order 
          entry (CPOE) market was valued at USD 1.1 billion in 2015

        
        - Health Information Exchange Market
          [https://www.grandviewresearch.com/industry-analysis/health-information-exchange-hie-market?utm_source=pressrelease&utm_medium=referral&utm_campaign=PRN_May15_Healthcare_CRO_RL4&utm_content=Content ]
          - The global health information exchange was market valued 
          at USD 988.6 million in 2015.

Grand View Research has segmented the global Healthcare Contract Research Organization (CRO) market report on the basis of type, service, and regions: 

        
        - Type (Revenue, USD Million, 2014 - 2024) 
             - Drug Discovery
                - Target validation
                - Lead identification
                - Lead optimization
             - Pre-Clinical
             - Clinical
                - Phase I Trial Services
                - Phase II Trial Services
                - Phase III Trial Services
                - Phase IV Trial Services
        - Service (Revenue, USD Million, 2014 - 2024) 
             - Project Management/Clinical Supply Management
             - Data Management
             - Regulatory/Medical Affairs
             - Medical Writing
             - Clinical Monitoring
             - Quality Management/ Assurance
             - Bio-statistics
             - Investigator Payments
             - Laboratory
             - Patient and site Recruitment
             - Technology
             - Others
        - Regional Outlook (Revenue, USD Million, 2014 - 2024) 
             - North America
                - U.S.
                - Canada
             - Europe
                - Germany
                - UK
                - France
             - Asia Pacific
                - Japan
                - China
                - India
             - Latin America
                - Brazil
                - Mexico
             - Middle East & Africa
                - South Africa

Explore the BI enabled intuitive market research database, The Grand Library [https://www.grandviewresearch.com/grand-library?utm_source=pressrelease&utm_medium=referral&utm_campaign=PRN_May15_Healthcare_CRO_BI&utm_content=Content ] , by Grand View Research, Inc.

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

        

        Contact: 
        Sherry James 
        Corporate Sales Specialist, USA 
        Grand View Research, Inc 
        Phone: +1-415-349-0058 
        Toll Free: 1-888-202-9519 
        Email: sales@grandviewresearch.com 

 

Web: https://www.grandviewresearch.com


    Photo: 
    https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg


SOURCE Grand View Research, Inc.